Drug Profile
Research programme: intranasal chlamydia vaccine - BlueWillow Biologics
Alternative Names: NE based chlamydia vaccine- BlueWillow BiologicsLatest Information Update: 27 Aug 2023
Price :
$50
*
At a glance
- Originator NanoBio Corporation
- Developer BlueWillow Biologics; Queensland University of Technology
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Chlamydial infections
Most Recent Events
- 27 Aug 2023 Intranasal chlamydia vaccine is still in preclinical development in Chlamydial-infections(Prevention) in Australia (Intranasal)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Chlamydial-infections(Prevention) in Australia (Intranasal)
- 07 May 2018 NanoBio Corporation is now called BlueWillow Biologics